Information Provided By: 
Fly News Breaks for September 22, 2017
AZN
Sep 22, 2017 | 07:31 EDT
Bernstein analyst Tim Anderson upgraded AstraZeneca, saying that the outlook of its current products has improved, leaving it well-positioned to grow even if its pipeline does not yield any new drugs through 2025. However, he adds that that the company "has one of the fullest Phase 3 pipelines in the group." Additionally, he is upbeat on the changes it is making and believes that its financial results will improve more quickly than those of its peers. Finally, he believes that it could become a takeover target. Target GBP5,780.
News For AZN From the Last 2 Days
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
